SOURCE: Medizone International, Inc.
SAN FRANCISCO, CA–(Marketwire – September 16, 2010) – Medizone International, Inc. (
Dr. Michael Shannon, Medizone’s Director of Medical Affairs, commented, “The CDC estimates that 100,000 people a year die from MRSA (staph infections). The CDC estimates 20% of hospital acquired MRSA infections cause death. Unfortunately, a new variant of MRSA is emerging within the broader community which has a much higher fatality rate, by some estimates reaching 50%. This newer variant is now being discovered in sports training facilities including those associated with professional, college and high school level teams. Recent investigations have revealed a broad range of bacteria at high concentration actually residing within unclean sports equipment which tend to be covered in mucus, sweat, dead skin and occasionally blood; ideal culture media for bacteria, fungi and mold. There have been a number of recent cases in which the use of contaminated sports equipment has lead to infections so severe that players, children in particular, have become critically ill from the resulting sepsis. So we believe that there is an obvious public health need to be addressed with AsepticSure™. Our technology is safe and we now have hard data to substantiate our claim of high efficacy in dealing with this growing community problem.”
Medizone’s CEO, Edwin Marshall, stated, “Our researchers have identified nuances in addressing the disinfection of sports equipment that again allows us to increase the patent protection wall being built around our AsepticSure™ sterilization system. We believe all of our recently filed additional patent applications, both US applications and international applications, will prove to greatly enhance the commercial value of our technology.”
Medizone International, Inc., is a research and development company engaged in developing its AsepticSure™ System to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. A government variant is being developed for bio-terrorism counter measures with additional variants for sports facilities and food processing applications.
This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.
Click here to see all recent news from this company